|
Market Closed -
Nasdaq
16:00:00 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 143.45 USD | -0.04% |
|
-8.09% | -21.46% |
| 10-14 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 10-08 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
Business description: Axsome Therapeutics, Inc.
Number of employees: 1,346
Sales by Activity: Axsome Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Developing and Delivering novel therapies for the management of CNS disorders | - | 50.04M | 271M | 386M | 638M |
Geographical breakdown of sales: Axsome Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | - | 50.04M | 197M | 378M | 629M |
Outside of The United States | - | - | 73.38M | 7.53M | 9.88M |
Executive Committee: Axsome Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2012-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 51 | 2018-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 42 | 2014-03-31 |
Ashley Dong
IRC | Investor Relations Contact | - | 2025-06-30 |
Ari Maizel
PRN | Corporate Officer/Principal | 47 | - |
Composition of the Board of Directors: Axsome Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 57 | 2012-01-11 | |
Roger Jeffs
BRD | Director/Board Member | 64 | 2014-11-30 |
Mark Coleman
BRD | Director/Board Member | 58 | 2014-11-30 |
Mark Saad
BRD | Director/Board Member | 56 | 2014-11-30 |
Susan Mahony
BRD | Director/Board Member | 61 | 2023-10-10 |
Company details: Axsome Therapeutics, Inc.
Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.04% | -8.09% | +7.59% | +131.07% | 7.52B | |
| +6.63% | +5.13% | +68.86% | +145.20% | 1,148B | |
| +1.53% | +2.84% | +47.48% | +89.01% | 652B | |
| +1.68% | +1.96% | +29.16% | +109.31% | 505B | |
| +0.73% | +2.47% | +53.85% | +68.96% | 384B | |
| +3.83% | -0.62% | +69.01% | +42.32% | 348B | |
| +2.38% | +4.27% | +33.81% | +57.95% | 294B | |
| +2.26% | +3.47% | +5.21% | +28.92% | 264B | |
| +1.97% | +3.01% | +57.91% | +76.14% | 244B | |
| +4.03% | +5.36% | +39.76% | +116.14% | 197B | |
| Average | +2.10% | +0.43% | +41.26% | +86.50% | 404.47B | |
| Weighted average by Cap. | +2.24% | +1.49% | +50.15% | +96.03% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AXSM Stock
- Company Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
